Kim Kyung-a, president of Samsung Bioepis, said in a New Year’s address on January 2, “The U.S. launch of biosimilars, including Pyzchiva, has been scheduled for 2025,” and noted, “The dedication and active participation of all employees are needed to achieve this goal.”
im made this statement in the context of the anticipated U.S. launch of Pyzchiva and the expected global approval of Obodence, a biosimilar to Prolia, and Xbryk, a biosimilar to Xgeva, later this year
Pyzchiva is a biosimilar to Stelara, an autoimmune disease treatment developed by Janssen. Prolia, developed by Amgen, is used for treating osteoporosis and bone loss in cancer patients, and it has also been approved under the product name Xgeva for the prevention of bone metastasis complications in cancer patients.
Kim emphasized that successful product launches and approvals require inter-departmental cooperation, as well as dedication and accountability in work,” adding, “Developing competitive products through operational efficiency and fostering continuous growth by embracing challenges are essential.”
She further announced, “This year, we will prepare for a second leap forward and create an opportunity to step up as a global corporation.”